Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001871 · ClinicalTrials.gov registry record

Study of Muscle Abnormalities in Patients With Specific Genetic Mutations

A clinical trial of Cardiomyopathy, Hypertrophic and Muscular Dystrophy, Oculopharyngeal, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
80
Enrollment target
1
Study location

NCT00001871 is a study of Cardiomyopathy, Hypertrophic and Muscular Dystrophy, Oculopharyngeal that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 80 participants, below the 360-participant average among 6 other Cardiomyopathy, Hypertrophic trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001871, a study of Cardiomyopathy, Hypertrophic and Muscular Dystrophy, Oculopharyngeal, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease affecting the heart. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle. This condition can cause patients to experience symptoms of chest pain, shortness of breath, fatigue, and heart beat palpitations. Researchers believe the disease may be caused by abnormalities in the genes responsible for producing proteins of the heart muscle. Oculopharyngeal muscular dystrophy (OPMD) is another genetically inherited disease. This condition affects the muscles of the eyes and throat causing symptoms of weak eye movements, difficulty swallowing and speaking, and weakness of the arms and legs. In previous studies researchers have found that several patients with hypertrophic cardiomyopathy (HCM) also had oculopharyngeal muscular dystrophy (OPMD). Researchers are interested in learning more about how these two diseases are associated with each other. In this study, researcher plan to collect samples of muscles (skeletal muscle biopsies) from patients belonging to families in which several members have inherited one or both of these diseases. The muscle samples will be used to link the muscle abnormalities with the specific genetic mutations. Patients participating in this study may not be directly benefited by it. However, information gathered because of this study may be used to develop better techniques for diagnosing and treating these conditions.

Study Locations (1)

Maryland

  • National Heart, Lung and Blood Institute (NHLBI) - Bethesda

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 1999-01
Est. Completion 2001-03

What the Registry Record Tells You About NCT00001871

The ClinicalTrials.gov registry entry for NCT00001871 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 360-participant average among 6 other Cardiomyopathy, Hypertrophic trials with a reported enrollment target (78% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cardiomyopathy, Hypertrophic appearing as the primary indexed condition, and to 0 interventions.

NCT00001871 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00001871 about?

NCT00001871 is a clinical study titled "Study of Muscle Abnormalities in Patients With Specific Genetic Mutations". Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease affecting the heart. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle. This condition can cause patients to experience symptoms of chest pain, shortness...

What is the current status of trial NCT00001871?

This trial is currently completed. The enrollment target is 80 participants. The study started on 1999-01. Estimated completion is 2001-03.

What conditions does trial NCT00001871 study?

This clinical trial studies the following conditions: Cardiomyopathy, Hypertrophic, Muscular Dystrophy, Oculopharyngeal.

Who is sponsoring clinical trial NCT00001871?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001871 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiomyopathy, Hypertrophic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.